コンテンツへスキップ
Merck
  • A common variant in PNPLA3, which encodes adiponutrin, is associated with liver fat content in humans.

A common variant in PNPLA3, which encodes adiponutrin, is associated with liver fat content in humans.

Diabetologia (2009-02-19)
A Kotronen, L E Johansson, L M Johansson, C Roos, J Westerbacka, A Hamsten, R Bergholm, P Arkkila, J Arola, T Kiviluoto, R M Fisher, E Ehrenborg, M Orho-Melander, M Ridderstråle, L Groop, H Yki-Järvinen
要旨

It has recently been suggested that the rs738409 G allele in PNPLA3, which encodes adiponutrin, is strongly associated with increased liver fat content in three different ethnic groups. The aims of the present study were as follows: (1) to try to replicate these findings in European individuals with quantitative measures of hepatic fat content; (2) to study whether the polymorphism influences hepatic and adipose tissue insulin sensitivity; and (3) to investigate whether PNPLA3 expression is altered in the human fatty liver. We genotyped 291 Finnish individuals in whom liver fat had been measured using proton magnetic resonance spectroscopy. Hepatic PNPLA3 expression was measured in 32 participants. Hepatic and adipose tissue insulin sensitivities were measured using a euglycaemic-hyperinsulinaemic (insulin infusion 0.3 mU kg(-1) min(-1)) clamp technique combined with infusion of [3-(3)H]glucose in 109 participants. The rs738409 G allele in PNPLA3 was associated with increased quantitative measures of liver fat content (p = 0.011) and serum aspartate aminotransferase concentrations (p = 0.002) independently of age, sex and BMI. Fasting serum insulin and hepatic and adipose tissue insulin sensitivity were related to liver fat content independently of genotype status. PNPLA3 mRNA expression in the liver was positively related to obesity (r = 0.62, p < 0.0001) and to liver fat content (r = 0.58, p = 0.025) in participants who were not morbidly obese (BMI < 40 kg/m(2)). A common variant in PNPLA3 increases the risk of hepatic steatosis in humans.

材料
製品番号
ブランド
製品内容

Sigma-Aldrich
リパーゼ Candida rugosa由来, Type VII, ≥700 unit/mg solid
Sigma-Aldrich
リパーゼ ブタ膵臓由来, Type II, ≥125 units/mg protein (using olive oil (30 min incubation)), 30-90 units/mg protein (using triacetin)
Sigma-Aldrich
リパーゼ・アクリル樹脂 from Candida antarctica, ≥5,000 U/g, recombinant, expressed in Aspergillus niger
Sigma-Aldrich
リパーゼ ブタ膵臓由来, Type VI-S, ≥20,000 units/mg protein, lyophilized powder
Sigma-Aldrich
リパーゼB, Candida antarctica由来, 組換え体 from Aspergillus oryzae, powder, beige, ~9 U/mg
Sigma-Aldrich
リパーゼ from Aspergillus niger, powder (fine), ~200 U/g
Sigma-Aldrich
リパーゼ Candida rugosa由来, lyophilized powder, ≥40,000 units/mg protein
Sigma-Aldrich
Lipase immobilized from Candida antarctica, beads, slightly brown, >2 U/mg
Sigma-Aldrich
リパーゼ Candida sp.(カンジダ属)由来, recombinant, expressed in Aspergillus niger
Sigma-Aldrich
リパーゼ from Rhizomucor miehei, ≥20,000 U/g
Sigma-Aldrich
リパーゼ Pseudomonas cepacia由来, powder, light beige, ≥30 U/mg
Sigma-Aldrich
リパーゼ コムギ胚芽由来, Type I, lyophilized powder, 5-15 units/mg solid
Sigma-Aldrich
リパーゼ from Rhizopus oryzae, powder (fine), ~10 U/mg
Sigma-Aldrich
リパーゼ from Aspergillus oryzae, lyophilized, powder, white, ~50 U/mg
Sigma-Aldrich
リパーゼ Pseudomonassp. (シュードモナス)由来, Type XIII, lyophilized powder, ≥15 units/mg solid
Sigma-Aldrich
リパーゼ Candida rugosa由来, powder, yellow-brown, ≥2 U/mg
Sigma-Aldrich
リパーゼ Candida rugosa由来, lyophilized, powder (fine), 15-25 U/mg
Sigma-Aldrich
リパーゼ from Mucor miehei, lyophilized powder, ≥4,000 units/mg solid (using olive oil)
Sigma-Aldrich
リパーゼ from Mucor miehei, powder, slightly brown, ~1 U/mg
Sigma-Aldrich
リパーゼ from Rhizopus niveus, powder (fine), ≥1.5 U/mg
Sigma-Aldrich
リパーゼ from Mucor javanicus, lyophilized powder, ≥300 units/mg solid (using olive oil)
Sigma-Aldrich
Lipase A Candida antarctica, recombinant from Aspergillus oryzae, powder, beige, ~2 U/mg